Our robust pipeline comprises high value proprietary assets.

To create and capture the value of our pipeline we have built a strong, vibrant network between academia and various strategic partners, enabling us to leverage their strengths and capabilities, alongside our own, to progress our pipeline safely and expediently through the clinic.


NVG-111 is a first-in-class Receptor Tyrosine Kinase Like Orphan Like Receptor 1 (ROR1) bispecific antibody T-cell engager for hematological and solid tumors. Initially the NVG-111 program will focus on Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma. It is designed to be highly effective in the killing of cancer cells, without the depletion of normal B cells.

NVG-111 can target cancer initiating stem cells (CSCs), a subpopulation of cancer cells that are resistant to standard cancer therapies and is believed to be the only T cell engager in development that can kill CSCs, potentially reducing the risk of tumor recurrence. Our proprietary CD3 targeting binder has been humanized and engineered for optimal activation of T cells for the efficient killing of tumor targets without excessive release of cytokines.

Pre clinical data for NVG-111 elicits potent killing of lymphoma cells including Primary CLL cells

Gohil et al https://doi.org/10.1080/2162402X.2017.1326437 and https://doi.org/10.1111/bjh.15911

Futher reading


We are changing the paradigm of cancer therapy with our immunotherapy technology

Read more

Patients and Families

We work with families and patient organisations to ensure our programmes deliver the best treatments for patients.

Read more